SCHEMBL20071890

SCHEMBL20071890

CC(C)(C)c1ccc2c(c1)N(c1ccc(-c3ccccc3)nc1)C(C1N(c3ccc(-c4ccccc4)nc3)c3ccc(C(C)(C)C)cc3N1c1ccc(-c3ccccc3)nc1)N2c1ccc(-c2ccccc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.43
CHRNA7 P36544 2/20 0.43
CHRNA4 P43681 2/20 0.43
LMNA P02545 1/20 0.35
MCHR1 Q99705 2/20 0.33
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
MAPT P10636 1/20 0.33
XBP1 P17861 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LDHA P00338 1/20 0.33
CYP3A4 P08684 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
FABP3 P05413 1/20 0.32
RARA P10276 1/20 0.32
RARB P10826 1/20 0.32
RARG P13631 1/20 0.32
RXRA P19793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20062898 0.82 CHRNB2 (0.40) CHRNB2CHRNA7CHRNA4LMNAMCHR1
SCHEMBL20681898 0.80 TP53 (0.33) NPSR1MEN1KMT2A
SCHEMBL20681869 0.76 MAPT (0.31) MAPT
SCHEMBL20681879 0.75 MEN1 (0.39) LMNAMAPTXBP1NPSR1MEN1
SCHEMBL20681861 0.74 KIF11 (0.44) LMNACYP11B1CYP11B2MAPTCYP3A4
SCHEMBL12245311 0.74 LDHA (0.47) CHRNB2CHRNA7CHRNA4CYP11B1CYP11B2
SCHEMBL29958189 0.74 LDHA (0.47) CHRNB2CHRNA7CHRNA4CYP11B1CYP11B2
SCHEMBL20071844 0.72 HTR3A (0.37) LMNACYP11B1CYP11B2CYP3A4
SCHEMBL20681894 0.71 ALDH1A1 (0.33) MAPTMEN1KMT2A
SCHEMBL20071949 0.70 KIF11 (0.41) MAPTRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 CHRNB2 1291/4885CHRNA7 1463/4885CHRNA4 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.